Bessemer Group Inc. Continues to Hold Stake in Heska Corporation (HSKA)
Bessemer Group Inc. held its position in shares of Heska Corporation (NASDAQ:HSKA) during the second quarter, Holdings Channel reports. The institutional investor owned 9,400 shares of the medical research company’s stock at the end of the second quarter. Bessemer Group Inc.’s holdings in Heska Corporation were worth $959,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently modified their holdings of HSKA. Riverbridge Partners LLC increased its position in shares of Heska Corporation by 257.0% in the first quarter. Riverbridge Partners LLC now owns 244,031 shares of the medical research company’s stock worth $25,618,000 after buying an additional 175,674 shares during the period. Neuberger Berman Group LLC increased its position in shares of Heska Corporation by 60.8% in the first quarter. Neuberger Berman Group LLC now owns 445,245 shares of the medical research company’s stock worth $46,742,000 after buying an additional 168,293 shares during the period. Vanguard Group Inc. increased its position in shares of Heska Corporation by 47.0% in the first quarter. Vanguard Group Inc. now owns 350,609 shares of the medical research company’s stock worth $36,807,000 after buying an additional 112,115 shares during the period. Dimensional Fund Advisors LP bought a new position in shares of Heska Corporation during the first quarter worth $5,853,000. Finally, Principal Financial Group Inc. bought a new position in shares of Heska Corporation during the first quarter worth $5,234,000. Institutional investors own 79.81% of the company’s stock.
Heska Corporation (NASDAQ:HSKA) opened at 97.67 on Wednesday. The company’s 50-day moving average is $101.39 and its 200-day moving average is $96.36. The company has a market cap of $705.76 million, a P/E ratio of 49.78 and a beta of 0.82. Heska Corporation has a 12 month low of $46.51 and a 12 month high of $115.00.
Heska Corporation (NASDAQ:HSKA) last released its earnings results on Thursday, August 3rd. The medical research company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $34.30 million during the quarter, compared to analysts’ expectations of $33.35 million. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. Heska Corporation’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the business earned $0.35 EPS. On average, equities research analysts expect that Heska Corporation will post $2.04 EPS for the current fiscal year.
WARNING: This article was reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/16/bessemer-group-inc-continues-to-hold-stake-in-heska-corporation-hska.html.
HSKA has been the topic of a number of research analyst reports. Zacks Investment Research upgraded shares of Heska Corporation from a “hold” rating to a “buy” rating and set a $101.00 price objective on the stock in a research report on Thursday, May 4th. BidaskClub downgraded shares of Heska Corporation from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. Aegis initiated coverage on shares of Heska Corporation in a research report on Thursday, June 1st. They set a “buy” rating and a $114.50 price objective on the stock. B. Riley restated a “neutral” rating and set a $83.00 price objective on shares of Heska Corporation in a research report on Friday, April 28th. Finally, Benchmark Co. restated a “buy” rating and set a $120.00 price objective (up previously from $106.00) on shares of Heska Corporation in a research report on Wednesday, August 9th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $105.20.
In other Heska Corporation news, insider Michael J. Mcginley sold 11,189 shares of Heska Corporation stock in a transaction that occurred on Wednesday, May 31st. The shares were sold at an average price of $98.53, for a total transaction of $1,102,452.17. Following the completion of the sale, the insider now directly owns 111,877 shares in the company, valued at approximately $11,023,240.81. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jason A. Napolitano sold 5,000 shares of Heska Corporation stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $100.50, for a total transaction of $502,500.00. The disclosure for this sale can be found here. Insiders sold a total of 30,265 shares of company stock valued at $2,983,439 over the last quarter. 14.70% of the stock is owned by company insiders.
About Heska Corporation
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corporation (NASDAQ:HSKA).
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.